September 19, 2018 08:03 AM EDT

Silverback starts to slowly edge out of stealth mode — but there’s still plenty being kept under wraps

John Carroll

Editor & Founder

Silverback Therapeutics was one of those stealthy biotechs that some tech writers loved to try and track. The company surfaced when backers recruited a high …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Silverback starts to slowly edge out of stealth mode — but there’s still plenty being kept under wraps

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

New CBER chief Prasad is readying 'massive framework' around vaccines, Makary says

Bristol Myers CEO says America’s biopharma pole position is not guaranteed

Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B

Roche could rethink $50B US expansion plan if new policies 'harm' operations

Sil­ver­back starts to slow­ly edge out of stealth mode — but there’s still plen­ty be­ing kept un­der wraps

Editor & Founder

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Silverback starts to slowly edge out of stealth mode — but there’s still plenty being kept under wraps